Graves Ophthalmopathy clinical trials

Explore recruiting graves ophthalmopathy clinical trials.

Recruiting graves ophthalmopathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Graves Ophthalmopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Treatment of Graves´ ophthalmopathy with diclofenak or simvastatin

Sweden

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects with Active, Moderate to Severe Thyroid Eye Disease (TED)

Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

The use of [68Ga]Ga-FAPI PET/MRI in assessing disease activity in patients with Graves’ orbitopathy

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects with Moderate-to-Severe Active Thyroid Eye Disease

France, Spain, Italy, Poland, Germany, Greece

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3b/4, Double-masked, Randomized, International, Parallel-assignment, Multicenter Trial in Patients with Thyroid Eye Disease to Evaluate the Safety and Tolerability of Different Dosing Durations of Teprotumumab

France, Italy, Germany, Spain

Phase III and phase IV (Integrated) EU CTIS Study details

Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) with Atorvastatin (ATORGO)

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Graves Ophthalmopathy trials by city

Graves Ophthalmopathy in Toronto Graves Ophthalmopathy in Vancouver Graves Ophthalmopathy in Montreal Graves Ophthalmopathy in Calgary Graves Ophthalmopathy in Edmonton Graves Ophthalmopathy in Ottawa Graves Ophthalmopathy in Winnipeg Graves Ophthalmopathy in Quebec City Graves Ophthalmopathy in Hamilton Graves Ophthalmopathy in Kitchener Graves Ophthalmopathy in London Graves Ophthalmopathy in Halifax Graves Ophthalmopathy in New York Graves Ophthalmopathy in Los Angeles Graves Ophthalmopathy in Chicago Graves Ophthalmopathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease